Search Results
Your search for ,WHo matches 21072 pages
Showing 1 - 50
Case 3: Metastatic RCC With Symptomatic Progression After IO/IO
This is Part 3 of Optimizing Patient Selection and Outcomes in Post-IO Advanced RCC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Hans Hammers, Michael Harrison, and Qian Qin discuss the treatment of metastatic renal cell...
Case 2: Advanced RCC With Mild Disease Progression After IO/IO
This is Part 2 of Optimizing Patient Selection and Outcomes in Post-IO Advanced RCC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Hans Hammers, Michael Harrison, and Qian Qin discuss the treatment of advanced renal cell...
Case 1: RCC With Disease Progression After Adjuvant Pembrolizumab
This is Part 1 of Optimizing Patient Selection and Outcomes in Post-IO Advanced RCC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Hans Hammers, Michael Harrison, and Qian Qin discuss the treatment of renal cell carcinoma...
Advanced Prostate Cancer: Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide
In a post hoc analysis of the phase III ARCHES and PROSPER trials reported in the Journal of Clinical Oncology, Armstrong et al found that radiographic progression (rPD) often occurred without prostate-specific antigen (PSA) rise in patients with advanced prostate cancer receiving the androgen...
Researchers Identify Blood-Based Biomarker for Cancer Risk in People With Lynch Syndrome
Researchers at The University of Texas MD Anderson Cancer Center have discovered a new blood-based biomarker that can help identify and characterize asymptomatic people with Lynch syndrome who are more susceptible to developing cancer based on early immune detection signatures, allowing clinicians...
Ulrich Steidl, MD, PhD, Named Director of Montefiore Einstein Comprehensive Cancer Center
International leader in blood cancer and stem cell research Ulrich Steidl, MD, PhD, has been named Director of the Montefiore Einstein Comprehensive Cancer Center (MECCC) and Vice President of Cancer Medicine at Montefiore Einstein. He has acted as Interim Director of MECCC, which is a National...
Final Report on Pralsetinib in Advanced RET Fusion–Positive NSCLC
As reported in the Journal of Clinical Oncology by Besse et al, the final report from the phase I/II ARROW trial supports the efficacy of the RET inhibitor pralsetinib in patients with advanced RET fusion–positive non–small cell lung cancer (NSCLC). The initial reports from the trial supported U.S. ...
Long-Term Outcomes With Pralsetinib in RET Fusion–Positive NSCLC
Long-term follow-up of the oral selective RET inhibitor pralsetinib in patients with advanced non–small cell lung cancer (NSCLC) and a RET fusion confirms its efficacy and safety, according to final findings from the phase I/II ARROW trial published in the Journal of Clinical Oncology. “Before...
Japanese Study Looks at Rates of Cancer Therapy–Related AML
Some therapies used to treat cancer may increase the risk of later developing secondary hematologic malignancies. A population-based study in Japan has revealed a gradual increase in the rates of therapy-related acute myeloid leukemia (tAML) in recent years—especially after breast cancer treatment. ...
Metastatic Papillary Renal Cancer: Final Results With Savolitinib and Durvalumab
As reported in the Journal of Clinical Oncology by Jackson-Spence et al, final results of the phase II CALYPSO study indicated better overall survival and other outcomes with savolitinib and durvalumab among patients with metastatic papillary renal cancer who have MET-driven disease. Study...
Low Food Access May Lead to More Complications After Breast Reconstruction
Researchers have identified a possible link between living in an area of lower food access and postoperative outcomes and complications after breast reconstruction, according to study results published in Plastic and Reconstructive Surgery. "Our findings suggest that access to healthy foods and...
Setidegrasib in Advanced NSCLC and Pancreatic Cancer Harboring the KRAS p.G12D Variant
In a phase I trial reported in The New England Journal of Medicine, Park et al identified the toxicity profile and preliminary antitumor activity of setidegrasib, a first-in-class KRAS G12D–targeted protein degrader, in patients with previously treated advanced non–small cell lung cancer (NSCLC) or ...
Ablative Radiotherapy May Improves Outcomes for Patients With ‘Supermassive’ Intrahepatic Cholangiocarcinoma
A new study published by Jaoude et al in Clinical Cancer Research demonstrates that a specialized high-dose type of radiation delivery may significantly improve outcomes for patients with large bile duct tumors in the liver, known as intrahepatic cholangiocarcinoma. The retrospective study was led ...
NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
The National Comprehensive Cancer Network® (NCCN®) brought together more than a thousand oncology professionals at the NCCN 2026 Annual Conference in Orlando, with hundreds more joining virtually. This year’s event featured educational sessions on breakthroughs in cancer prevention and treatment,...
Surgery Still Safe, Beneficial For Many Octogenarian Patients With NSCLC
Surgical treatment was found to be safe and demonstrate long-term quality-of-life benefits for carefully selected octogenarians with early-stage non–small cell lung cancer (NSCLC), according to findings from a prospective cohort study published in The Lancet Regional Health: Americas. “As our...
Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individuals were diagnosed with colorectal cancer, and approximately 53,000 individuals died from the...
Prompting Strategies May Improve Symptom Monitoring in Childhood Cancer Survivors
Prompting strategies on two large language models improved how the artificial intelligence (AI) interpreted pain and fatigue reported by survivors of childhood cancers for better symptom monitoring and care, according to findings published in Communications Medicine. The study authors noted that...
FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL
The U.S. Food and Drug Administration (FDA) has granted traditional approval to the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for adult patients with relapsed or refractory mantle cell lymphoma (MCL). The full approval now includes efficacy, safety, and...
Patients With Lung Cancer May Safely Receive Adequate SBRT Dosage in One Treatment
Many people with lung cancer can be treated with a highly precise, high dose of radiation given in just one session without compromising the effectiveness of the treatment. The treatment strategy, outlined in a new publication authored by Singh et al in the International Journal of Radiation...
Presence of ctDNA at the End of Neoadjuvant Therapy May Predict Breast Cancer Recurrence
Fragments of tumor DNA circulating in the bloodstream of patients with breast cancer may predict whether they are likely to experience relapse—especially when samples are taken after the patients have received treatments prior to surgery. Findings presented at the 15th European Breast Cancer...
Low-Risk Endometrial Cancer: Does a Lack of Adjuvant Therapy Affect Survival?
In a study reported in a research letter in JAMA Oncology, Matsuo et al found that survival without adjuvant therapy in women with low-risk endometrial cancer was poorer among those with isolated tumor cells (ITCs) vs no lymph node metastasis in regional lymph nodes. Study Details The cohort...
One-Time Low-Dose CT Screening May Reduce Lung Cancer Mortality Among Neversmokers in Asia
One-time low-dose computed tomography (CT) screening for lung cancer in a non–risk-based Chinese population led to a significant reduction in lung cancer mortality, according to the results of a prospective, nonrandomized, controlled study presented at the European Lung Cancer Congress 2026...
Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers
Researchers leading the LORD trial of active surveillance for ductal carcinoma in situ (DCIS) described early results as “reassuring” in a presentation to the 15th European Breast Cancer Conference (EBCC15) in Barcelona (Abstract 2LBA). People diagnosed with DCIS have abnormal cells inside the milk ...
Elinzanetant May Reduce Side Effects of Endocrine Therapy Among Patients With Breast Cancer
Results from the OASIS 4 clinical trial showed that elinzanetant, a neurokinin-targeted therapy, relieved hot flashes and night sweats that can occur because of menopause or hormone treatment for breast cancer. These findings were published in June 2025 in The New England Journal of Medicine. Now,...
Risk of Subsequent Cancer in Solid Organ Transplant Recipients With Pretransplant Cancer History
In a study reported in JAMA Oncology, Tao et al found that U.S. solid organ transplant (SOT) recipients with a history of pretransplant cancer were at increased risk of subsequent cancer. Study Details The cohort study used linked data from the U.S. Scientific Registry of Transplant Recipients and ...
Transdermal Estradiol Patches vs LHRH Agonists in Locally Advanced Prostate Cancer
As reported in The New England Journal of Medicine by Langley et al, a UK phase III trial (PATCH/STAMPEDE-1) has shown noninferiority in metastasis-free survival with the use of transdermal estradiol (tE2) patches vs luteinizing hormone–releasing hormone (LHRH) agonist treatment in men with locally ...
Molecular Test Doubles Detection of Bile Duct Cancer
When patients develop a narrowing or blockage in the bile ducts, physicians must determine whether the cause is cancer or a benign condition. The location of these blockages adds challenges to the diagnosis, and this uncertainty can delay treatment decisions for patients in the event they have this ...
Adjuvant Atezolizumab and mFOLFOX6 in Stage III Mismatch Repair–Deficient Colon Cancer
As reported in The New England Journal of Medicine by Sinicrope et al, the phase III ATOMIC trial has shown that the addition of adjuvant atezolizumab to mFOLFOX6 (modified fluorouracil, oxaliplatin, and leucovorin) improved disease-free survival in patients with resected stage III mismatch...
Radiotherapy May Reduce Risk of Lymphedema in Patients With Breast Cancer More Effectively Than Surgery
Patients with breast cancer may be able to avoid lymphedema, which can occur after surgery to remove lymph nodes in the axilla, by having radiotherapy instead. New findings, presented at the 15th European Breast Cancer Conference (EBCC15) in Barcelona, suggest that axillary radiotherapy may be as...
Two Major Cancer Centers Announce Appointments of New Directors
Last week, Dartmouth Cancer Center (DCC) and Fox Chase Cancer Center announced the appointments of new directors—both experts in the treatment of lung cancer. DCC has appointed Roy S. Herbst, MD, PhD, as the center’s sixth director. Temple Health announced the appointment of Robert A. Winn, MD, as...
Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis
In patients with CALR exon 9–mutated myelofibrosis who were resistant or intolerant to prior Janus kinase (JAK) inhibitor therapy, or ineligible for such treatment, the first-in-class mutant calreticulin–specific monoclonal antibody INCA033989, given as monotherapy or in combination with...
Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma
Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precursor Asymptomatic Neoplasms by Group Effort Analysis–Smoldering Multiple Myeloma (PANGEA-SMM),...
AI As Collaborator in Cancer Research and in Clinical Care
Last October, the Cancer AI Alliance (CAIA) announced the launch of its collaborative artificial intelligence (AI) platform powered by federated learning to train AI models with millions of de-identified patient datasets from participating cancer centers, while maintaining patient security,...
AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?
The promise of artificial intelligence (AI) technologies to provide highly personalized oncology care for patients and improve outcomes has been decades in the making. In a 1987 editorial in The New England Journal of Medicine, pioneering nephrologist and health economist William B. Schwartz, MD,...
Breast Cancer Recurrence Remains Low—Even After 10 Years—With Radiotherapy Tailored to Patient’s Individual Risk
The chances of breast cancer recurring remain low when patients are treated with radiotherapy that is tailored to their individual risk following chemotherapy and surgery. These are the findings of a 10-year Dutch study (RAPCHEM; BOOG 2010-03) presented at the 15th European Breast Cancer Conference ...
Breast Reconstruction Using Polyurethane-Coated Implants May Reduce the Risk of Capsular Contracture, Additional Surgery
Women who are treated with mastectomy for breast cancer often choose to have breast reconstructive surgery using an implant. But hard, painful scar tissue can form around the implant, especially when women also receive radiotherapy as part of their treatment. Findings from the OPBC-09 PRExRT study, ...
FDA Approves Relacorilant With Nab-Paclitaxel for Several Platinum-Resistant Gynecologic Cancers
On March 25, the U.S. Food and Drug Administration (FDA) approved relacorilant (Lifyorli), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
In Celebration of a Decades-Long Journey of Discovery and Innovation
On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds the titles of Director of Dana-Farber/Harvard Cancer Center, the Richard and Susan Smith Professor of ...
POEMS Syndrome: Diagnostic Clues From Neuropathy to Bone Marrow Findings
POEMS syndrome is a poorly understood and complex paraneoplastic plasma cell disorder characterized by peripheral neuropathy and multisystem involvement, including organomegaly, endocrinopathy, monoclonal plasma cell dyscrasia, and skin changes. Clinical manifestations are thought to result from...
A Decade of Research Leads to New Guidance on Using Colony-Stimulating Factors in Anticancer Treatment
ASCO has published an updated guideline describing the latest evidence on using hematopoietic colony-stimulating factor (CSF) to support anticancer treatment, namely chemotherapy and stem cell transplantation.1 “We wanted to update these guidelines both to include the newer evidence as well as...
AI Model Classifies Challenging Thymic Epithelial Tumors
A deep learning model can diagnose thymic epithelial tumors with high sensitivity for thymic carcinoma detection, according to findings published in Annals of Oncology. The researchers suggested that the tool could be used to improve diagnostic consistency and support decision-making in settings...
Myelofibrosis: Treatment Landscape Is Poised for Change
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Awareness of Alcohol-Cancer Link Holds Steady Despite Omission in New U.S. Dietary Guidelines, Survey Finds
Public awareness of the link between drinking alcohol and elevated cancer risk remains unchanged since February 2025, with over half of Americans saying that regularly consuming alcohol increases your chances of later developing cancer, according to a new survey by the Annenberg Public Policy...
Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk
Among patients with acute myeloid leukemia (AML) who were treated with intensive chemotherapy on clinical trials from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), Black race was found to be an independent predictor of inferior survival, with outcomes not being explained by cytogenetic risk....
Three AI-Enabled Analyses Highlight Context-Dependent Biomarkers in Early-Onset Colorectal Cancer
Biomarker discovery in colorectal cancer has traditionally focused on identifying molecular alterations with broad prognostic or predictive utility. However, evidence is increasingly suggesting that biomarkers do not have universal prognostic or predictive value across patient sets but instead...
The Thymus Plays a Part in Adult Cancer Risk and Treatment Response, Research Reveals
Two papers published in Nature reveal long-disregarded functions of the thymus in adulthood, showing that the overall health of the organ impacts aging and risks for cardiovascular disease and cancer, as well as affecting response to immunotherapy in patients with cancer. “The thymus has been...
Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers have found a combination of the tyrosine kinase inhibitor tucatinib and the monoclonal antibody trastuzumab, plus the chemotherapy capecitabine, may improve symptoms and extend survival in some...
Melanoma-Specific Survival With Sentinel Lymph Node Biopsy
In a systematic review and meta-analysis reported in The Lancet Oncology, Varey et al found that patients undergoing sentinel node biopsy (SLNB) for melanoma had reduced risk of melanoma-specific mortality and disease recurrence vs those who did not undergo SLNB. Study Details The analysis included ...
Breast Cancer: Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy
In a study (PREDICT-DNA) reported in the Journal of Clinical Oncology, Hunter et al found that an ultrasensitive assay for circulating tumor DNA (ctDNA) to detect measurable residual disease after neoadjuvant therapy in patients with breast cancer did not distinguish pathologic complete response...
